Key Takeaways
The law firm Pomerantz LLP is investigating Compass Therapeutics, Inc. (NASDAQ: CMPX) for securities fraud after the company’s stock plunged 64.4% following a clinical trial update.
The investigation concerns whether Compass and its officers may have engaged in unlawful business practices by not fully disclosing the risks and trial data. "Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc.," the firm announced on April 30, advising investors of their rights.
Compass shares fell $3.24 to close at $1.79 on April 27 after the company announced results for its phase 2/3 study of the drug tovecimig in patients with biliary tract cancer. While the company said the study met a key secondary endpoint of progression-free survival, it missed another key secondary endpoint of overall survival, raising questions about the drug's viability.
The sharp stock decline and subsequent investigation highlight the binary risks associated with biotech investments, where clinical trial outcomes can determine a company's fate. Pomerantz is a notable firm in securities litigation, having recently filed class-action lawsuits against other companies, including Gossamer Bio, Inc. (NASDAQ: GOSS) and Concorde International Group, Ltd. (NASDAQ: CIGL), for similar issues of alleged securities fraud.
The investigation adds a layer of legal risk on top of the clinical uncertainty facing the company. Investors will now watch for whether the investigation leads to a formal class-action lawsuit, which could result in significant financial penalties for Compass Therapeutics.
This article is for informational purposes only and does not constitute investment advice.
